share_log

Becton, Dickinson and (NYSE:BDX) Releases FY23 Earnings Guidance

Financial News Live ·  Feb 3, 2023 17:31

Becton, Dickinson and (NYSE:BDX – Get Rating) updated its FY23 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $12.07 to $12.32 for the period, compared to the consensus estimate of $11.97. Becton, Dickinson and also updated its FY 2023 guidance to $12.07-$12.32 EPS.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Morgan Stanley increased their price objective on shares of Becton, Dickinson and from $290.00 to $295.00 and gave the company an overweight rating in a research note on Friday. William Blair reaffirmed an outperform rating on shares of Becton, Dickinson and in a research note on Friday, November 11th. The Goldman Sachs Group dropped their price target on shares of Becton, Dickinson and from $319.00 to $272.00 and set a buy rating for the company in a research note on Wednesday, November 23rd. Evercore ISI dropped their price target on shares of Becton, Dickinson and to $270.00 in a research note on Wednesday, November 16th. Finally, Cowen dropped their price target on shares of Becton, Dickinson and to $255.00 in a research note on Wednesday, November 16th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus price target of $275.64.

Get Becton Dickinson and alerts:

Becton, Dickinson and Stock Down 1.1 %

NYSE:BDX traded down $2.63 during trading hours on Friday, reaching $245.84. The company had a trading volume of 2,117,712 shares, compared to its average volume of 1,236,927. The company has a quick ratio of 0.63, a current ratio of 1.04 and a debt-to-equity ratio of 0.55. The firm has a market cap of $69.88 billion, a price-to-earnings ratio of 41.81, a P/E/G ratio of 2.23 and a beta of 0.54. The business's 50-day simple moving average is $251.52 and its two-hundred day simple moving average is $244.40. Becton, Dickinson and has a twelve month low of $215.90 and a twelve month high of $280.62.

Becton, Dickinson and (NYSE:BDX – Get Rating) last posted its quarterly earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.30. Becton, Dickinson and had a net margin of 9.16% and a return on equity of 14.47%. The business had revenue of $4.59 billion during the quarter, compared to analysts' expectations of $4.59 billion. During the same period last year, the company posted $3.64 earnings per share. The business's quarterly revenue was down 2.8% on a year-over-year basis. On average, equities analysts expect that Becton, Dickinson and will post 11.94 earnings per share for the current year.

Becton, Dickinson and Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date of this dividend is Thursday, March 9th. Becton, Dickinson and's dividend payout ratio (DPR) is 61.90%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Zions Bancorporation N.A. lifted its position in shares of Becton, Dickinson and by 13.0% during the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier's stock valued at $134,000 after purchasing an additional 58 shares in the last quarter. Evergreen Capital Management LLC raised its position in Becton, Dickinson and by 0.6% in the first quarter. Evergreen Capital Management LLC now owns 12,238 shares of the medical instruments supplier's stock worth $3,255,000 after acquiring an additional 67 shares during the period. Global Wealth Management Investment Advisory Inc. raised its position in Becton, Dickinson and by 3.1% in the first quarter. Global Wealth Management Investment Advisory Inc. now owns 2,313 shares of the medical instruments supplier's stock worth $615,000 after acquiring an additional 69 shares during the period. Brighton Jones LLC raised its position in Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier's stock worth $368,000 after acquiring an additional 112 shares during the period. Finally, Orion Portfolio Solutions LLC raised its position in Becton, Dickinson and by 10.7% in the first quarter. Orion Portfolio Solutions LLC now owns 1,181 shares of the medical instruments supplier's stock worth $314,000 after acquiring an additional 114 shares during the period. 87.08% of the stock is owned by institutional investors.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

See Also

  • Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
  • Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
  • Zimmer Biomet Beats on Earnings, Growth May be Priced In
  • AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
  • Ford Stock Going Forward After Big Earnings Flop
  • Insiders And Institutions Buy Wolverine Worldwide

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment